Reserved Targets. During the period prior to the [***] anniversary of the Effective Date and prior to selection of [***] Additional Targets, BMS shall have the right to designate a total of up to [***] Targets as reserved Targets (each, a “Reserved Target”) in accordance with this Section 2.3.2 and the gatekeeper process set forth in Section 2.3.3. The maximum number of Reserved Targets shall decrease following the selection of each Additional Target [***] as follows: (a) upon selection of the [***] Additional Target by BMS (regardless of whether such Additional Target is a Reserved Target), the maximum number of Reserved Targets shall be [***] and, if BMS had previously designated [***] Reserved Targets, then, immediately upon receipt of the Target Availability Notice confirming such Additional Target is Available in accordance with Section 2.3.3, BMS shall provide written notice to the Gatekeeper and to MTEM identifying which of the previously designated Reserved Targets will cease to be a Reserved Target (and, thereafter, such Target will be deemed a Terminated Target); and (b) upon selection of the [***] Additional Target by BMS (regardless of whether such Additional Target is a Reserved Target), the remaining Target(s) that were previously designated Reserved Target(s) shall cease to be Reserved Target(s) and, thereafter, such Target(s) will be deemed Terminated Target(s). Subject to the foregoing and the remainder of this Section 2.3.2, if a Target that BMS identifies as a proposed Reserved Target in a Target Nomination Notice is Available, as determined in accordance with the gatekeeper process set forth in Section 2.3.3, then such Target shall be designated as a Reserved Target from [***] until the earlier of (i) the date that is [***] after the date of such Target Availability Notice or (ii) BMS’ selection of Additional Targets as provided above (the “Reservation Period”). [***]. For clarity, upon expiration of the Reservation Period with respect to each Reserved Target [***] and, in any event, upon BMS’ selection of [***] Additional Targets, regardless of whether such Additional Target(s) were Reserved Targets, each Reserved Target [***] shall cease to be a Reserved Target, each such Target shall be deemed a Terminated Target, and the terms of Section 5.6 shall no longer apply to such Target.
Reserved Targets. Exhibit G identifies the Reserved Targets (as further described in Section 3.3(d) below.
Reserved Targets. During the Extended Collaboration Term Lilly may designate any Target related to a Collaboration Therapeutic Area as a “Reserved Target,” [***]. Lilly shall provide written notice to Isis identifying each Target that Lilly desires to designate as a Reserved Target. The date upon which Isis receives such notice shall be deemed the “Reserved Target Notice Date.” [***]
Reserved Targets. The Parties agree that:
Reserved Targets. The Parties acknowledge that , as of the Effective --------------------- Date, there are certain Targets with respect to which Pharmacopeia may have obligations under its existing agreements with Third Parties, and that Pharmacopeia will not conduct certain research activities with respect to such Targets in connection with the Collaboration (each such Target a "Reserved Target"). SPL shall not knowingly request Pharmacopeia to develop assays with respect to, or screen any Libraries against, such Reserved Targets. * In the event that during the term of the Collaboration Pharmacopeia's Third Party obligations with respect to a given Reserved Target expire, or such Reserved Target otherwise becomes available for unrestricted use in the Collaboration, Pharmacopeia shall promptly notify SPL and such Target shall thereafter cease to be a Reserved Target. It is further __________________ * CONFIDENTIAL TREATMENT REQUESTED understood and agreed that, notwithstanding any other provision of this Agreement, Pharmacopeia shall not be obligated to conduct any activities in performance of the Collaboration that would constitute a breach of any of its obligations to any Third Party.
Reserved Targets. If BioNTech desires to reserve an Available Nominated Target, then BioNTech shall notify both Autolus and the Gatekeeper in writing of the identity of such Nominated Target within [***] after BioNTech’s receipt of an Availability Notice, including the name, aliases, and UniProt/SwissProt database identifier for such Nominated Target (a “Reserved Target”). Autolus shall not enter into an agreement with a Third Party for Other AE Licensed Products directed to such Reserved Target if such agreement would prejudice BioNTech’s option rights to such Reserved Target until the end of the Module Option Period. For clarity, [***]. During the Module Option Period, BioNTech may designate [***], and may [***]. For clarity, [***].
Reserved Targets. Gene (Disease/Protein) – Uniprot ID [***]
Reserved Targets. Subject to the terms and conditions of this Section 2.3.1 (Reserved Targets) and Section 11.3 ([*] Reservation Fee Per Target), at any given time during the Collaboration Term, Gilead may designate up to three (3) Targets in total (other than any Target that is deemed to be a Collaboration Target, Tabled Target or Excluded Target at such time) that will be subject to the exclusivity obligations set forth in Section 2.9 (Exclusivity) (each, a
Reserved Targets. The Parties will select certain gene targets to be reserved (each such reserved gene target, a “Reserved Target”) for potential selection as Oncology Targets under this Agreement according to the following schedule:
Reserved Targets. The discovery, research or development of an ASO that is designed to bind to the RNA that encodes any of the Reserved Targets, from the date each such oncology gene target becomes a Reserved Target under Section 3.3.5 until the date such Reserved Target ceases to be a Reserved Target by operation of Section 3.3.6;
